Treatment Breakthrough for Breast Cancer
Treating advanced hormone receptor-positive, HER2-negative breast cancer patients with AstraZeneca’s experimental pill camizestrant upon early signs of resistance significantly reduces the risk of disease progression or death by 56%. Presented at the ASCO meeting, this approach utilizes blood tests to detect early drug resistance, allowing timely treatment adjustments before tumor growth is visible. Researchers found that patients receiving camizestrant had a progression-free survival of 16 months compared to 9.2 months for those on standard therapy, indicating a potential shift in treatment practices.